Corresponding author: Shi Hu
Affiliations: Second Military Medical University
Publication date: this article was published online on April 24, 2020
DOI: http://doi.org/10.1038/s41467-020-16048-4
Highlights
The researchers generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, they also demonstrated that the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro.
Nomination Reason
This work reveals that an ACE2-Ig exhibit cross-reactivity against coronaviruses, and have potential applications in the diagnosis, prophylaxis, and treatment of SARS-CoV-2.
----------------------------------------------------------------------------------------------------------------------------------------------
This article has been nominated for Distinguished Research Awards, you can visit the website below and vote for the nominated publications:
https://www.molecularcloud.org/awards-for-distinguished-research.html.
About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they have potential applications in the diagnosis, prophylaxis, and treat
All of the paper is very good!
I can share this paper:/10.1080/19420862.2020.1804241
I think ACE2-Fc is the best anti-virus antibody-lile molecular. It is not only bindings to SARS-CoV-2, and many in the future to bind a unkown pathgen
All the paper is very interesting!
Also for this :Chan K K, Dorosky D, Sharma P, et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2[J]. Science, 2020, 369(6508): 1261-1265.
I recomment this preprint:10.1101/2020.03.16.994236:The rapid and escalating spread of SARS coronavirus 2 (SARS-CoV-2) poses an immediate public health emergency. The viral spike protein S binds ACE2 on host cells to initiate molecular events that release the viral genome intracellularly. Soluble ACE2 inhibits entry of both SARS and SARS-2 coronaviruses by acting as a decoy for S binding sites, and is a candidate for therapeutic, prophylactic and diagnostic development. Using deep mutagenesis, variants of ACE2 are identified with increased binding to the receptor binding domain of S. Mutations are found across the interface, in the N90-glycosylation motif, and at buried sites where they are predicted to enhance local folding and presentation of the interaction epitope. When single substitutions are combined, large increases in binding can be achieved. The mutational landscape offers a blueprint for engineering high affinity proteins and peptides that block receptor binding sites on S to meet this unprecedente
Is there any chance to sceen a smal molecular weigh peptide to act like ace2?
For reference:Li Y, Wang H, Tang X, et al. Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1[J]. bioRxiv, 2020.
This work is very inteseting!